Get started
Janux Therapeutics, Inc.Janux Therapeutics, Inc.Janux Therapeutics, Inc.

Janux Therapeutics, Inc.

No trades
Buy JANX
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

JANX chart


Full chart

Key facts today

Avalon Ventures XI cut its stake in Janux Therapeutics, Inc. to 4,090,318 shares by selling 594,152 shares on October 23 and 24. In 2024, Janux shares rose about 400%.
Analyze the impactAnalyze the impact

Upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.82 B‬USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.92USD
Net income (FY)
‪−58.29 M‬USD
Revenue (FY)
‪8.08 M‬USD
Shares float
‪41.24 M‬
Beta (1Y)
2.46

Employees


Employees (FY)
64
Change (1Y)
+4 +6.67%
Revenue / Employee (1Y)
‪126.30 K‬USD
Net income / Employee (1Y)
‪−910.83 K‬USD

About Janux Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
David Campbell
Website
januxrx.com
Headquarters
San Diego
Founded
2017
FIGI
BBG00ZHSKH11
Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas



See all ideas 

News



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of JANX is 54.39 USD — it has decreased by −3.50% in the past 24 hours. Watch Janux Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Janux Therapeutics, Inc. stocks are traded under the ticker JANX.
JANX stock has risen by 2.47% compared to the previous week, the month change is a 19.58% rise, over the last year Janux Therapeutics, Inc. has showed a 735.48% increase.
We've gathered analysts' opinions on Janux Therapeutics, Inc. future price: according to them, JANX price has a max estimate of 100.00 USD and a min estimate of 42.00 USD. Watch JANX chart and read a more detailed Janux Therapeutics, Inc. stock forecast: see what analysts think of Janux Therapeutics, Inc. and suggest that you do with its stocks.
JANX reached its all-time high on May 3, 2024 with the price of 65.60 USD, and its all-time low was 5.65 USD and was reached on Nov 10, 2023. View more price dynamics on JANX chart.
See other stocks reaching their highest and lowest prices.
JANX stock is 6.19% volatile and has beta coefficient of 2.46. Track Janux Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Janux Therapeutics, Inc. there?
Today Janux Therapeutics, Inc. has the market capitalization of ‪2.82 B‬, it has increased by 4.95% over the last week.
Yes, you can track Janux Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Janux Therapeutics, Inc. is going to release the next earnings report on Nov 5, 2024. Keep track of upcoming events with our Earnings Calendar.
JANX earnings for the last quarter are −0.11 USD per share, whereas the estimation was −0.31 USD resulting in a 64.60% surprise. The estimated earnings for the next quarter are −0.33 USD per share. See more details about Janux Therapeutics, Inc. earnings.
Janux Therapeutics, Inc. revenue for the last quarter amounts to ‪8.90 M‬ USD, despite the estimated figure of ‪772.00 K‬ USD. In the next quarter, revenue is expected to reach ‪1.50 M‬ USD.
JANX net income for the last quarter is ‪−5.96 M‬ USD, while the quarter before that showed ‪−14.76 M‬ USD of net income which accounts for 59.63% change. Track more Janux Therapeutics, Inc. financial stats to get the full picture.
No, JANX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 2, 2024, the company has 64.00 employees. See our rating of the largest employees — is Janux Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Janux Therapeutics, Inc. EBITDA is ‪−63.86 M‬ USD, and current EBITDA margin is −878.68%. See more stats in Janux Therapeutics, Inc. financial statements.
Like other stocks, JANX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Janux Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Janux Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Janux Therapeutics, Inc. stock shows the strong buy signal. See more of Janux Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.